Q-omics provides the consensus-scored UROC1 profile across patient tissues and cancer cell-line models. UROC1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, UROC1 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, UROC1 RNA expression shows 11,293 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, and TGCT as cancer lineages where UROC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UROC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UROC1 survival associations across molecular data types. UROC1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UROC1 RNA expression–survival associations across cancer types. High UROC1 expression shows unfavorable associations in KIRC, THCA, CHOL, KICH and DLBC, but favorable associations in LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for UROC1 RNA expression.
This table summarizes UROC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for UROC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UROC1 shows lower tumor expression in LIHC and CHOL and higher tumor expression in KIRC, KIRP, COAD and STAD. The KIRC box plot shows higher UROC1 RNA expression in tumor versus normal tissue (log2 FC = +0.070, t-test p < 0.001).
This table shows molecular features associated with UROC1 in patient tissues and cancer cell lines. In patient samples, UROC1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, UROC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and LARGE_INTESTINE.
